Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Chongqing Genrix Biopharmaceutical Co PB Ratio?
Chongqing Genrix Biopharmaceutical CoSHSE:688443 +0.81%48 PB Ratio is 6.39 as of Jul. 21, 2026, which is 21% above its 10-year median of 5.27. GuruFocus rates SHSE:688443 with a GF Score™ of 48/100. The stock has 4 warning signs investors should review. Among 1,229 Biotechnology companies, Chongqing Genrix Biopharmaceutical Co ranks worse than 76.48% on this metric.
SHSE:688443's PB Ratio is ranked worse than 76.48% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs SHSE:688443: 6.40
During the past 12 months, Chongqing Genrix Biopharmaceutical Co's average Book Value Per Share Growth Rate was -28.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 244.20% per year.
During the past 7 years, the highest 3-Year average Book Value Per Share Growth Rate of Chongqing Genrix Biopharmaceutical Co was 244.20% per year. The lowest was 72.30% per year. And the median was 158.25% per year.
Back to Basics: PB Ratio
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Chongqing Genrix Biopharmaceutical Co PB Ratio Related Terms
Chongqing Genrix Biopharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chongqing Genrix Biopharmaceutical Co PB Ratio Chart
SHSE:688443 vs VRTX, REGN, ALNY: PB Ratio Comparison
For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chongqing Genrix Biopharmaceutical Co PB Ratio vs Biotechnology Industry
Chongqing Genrix Biopharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a PB Ratio of 6.39 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. This is 21% above median its historical median of 5.27. Over the past decade, Chongqing Genrix Biopharmaceutical Co's PB Ratio has ranged from 3.30 to 8.04. According to the industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #940 out of 1229 companies in the Biotechnology industry, placing it in the top 76.5%.
Is Chongqing Genrix Biopharmaceutical Co's PB Ratio too high?
Chongqing Genrix Biopharmaceutical Co's current PB Ratio of 6.39 is 21% above median its 10-year median of 5.27. Over the past 10 years, this metric has ranged from a low of 3.30 to a high of 8.04. The Biotechnology industry median PB Ratio is 2.79. Chongqing Genrix Biopharmaceutical Co's value of 6.39 is 129% above this industry median. Based on the distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #940 out of 1229 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chongqing Genrix Biopharmaceutical Co has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Chongqing Genrix Biopharmaceutical Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chongqing Genrix Biopharmaceutical Co ranks #940 out of 1229 companies for PB Ratio. This places Chongqing Genrix Biopharmaceutical Co in the lower half of its industry. The industry median PB Ratio is 2.79. Chongqing Genrix Biopharmaceutical Co's value of 6.39 is 129% above this benchmark. Historically, Chongqing Genrix Biopharmaceutical Co's own PB Ratio has ranged from 3.30 to 8.04 over the past decade. While the company's 10-year median is 5.27 vs. the industry median of 2.79, Chongqing Genrix Biopharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chongqing Genrix Biopharmaceutical Co's current PB Ratio of 6.39 is 129% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Chongqing Genrix Biopharmaceutical Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chongqing Genrix Biopharmaceutical Co's current PB Ratio is 6.39, which is 21% above median its own 10-year median of 5.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chongqing Genrix Biopharmaceutical Co stock overvalued right now?
Chongqing Genrix Biopharmaceutical Co (SHSE:688443) has a current PB Ratio of 6.39. The current PB Ratio is 6.39, which is 21% above median its 10-year median of 5.27 and 129% above the Biotechnology industry median of 2.79. Chongqing Genrix Biopharmaceutical Co's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Chongqing Genrix Biopharmaceutical Co (SHSE:688443), the current PB Ratio is 6.39 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Chongqing Genrix Biopharmaceutical Co Business Description
Chongqing Genrix Biopharmaceutical Co Ltd is a biopharmaceutical company engaged in the research & development, production and sales of antibody drugs. The company's pipeline includes product candidate that targets Autoimmune Diseases, Infectious Diseases, and Oncology.
48GF Score
Get the complete analysis for SHSE:688443
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688443 has been successfully added to your 
